RT Journal Article SR Electronic T1 CD44 Expression Is a Prognostic Factor in Patients with Intrahepatic Cholangiocarcinoma After Surgical Resection JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 5701 OP 5705 VO 37 IS 10 A1 YUJI MORINE A1 SATORU IMURA A1 TETSUYA IKEMOTO A1 SHUICHI IWAHASHI A1 YU SAITO A1 MITSUO SHIMADA YR 2017 UL http://ar.iiarjournals.org/content/37/10/5701.abstract AB Background/Aim: Cancer stem cells (CSC) plays an important role in various kinds of cancers. The aim of this study was to clarify the role of CD44 expression in intrahepatic cholangiocarcinoma (IHCC) as a marker of CSCs. Materials and Methods: Thirty-five patients with IHCC patients who underwent hepatectomy were evaluated. CD44 expression was determined immunohistochemically. The patients were divided into a CD44-positive group (n=22) or CD44-negative group (n=13). Clinicopathological variables including prognosis were compared between the two groups. Results: The CD44-positive group had a worse prognosis than the CD44-negative group (5-year survival: 19.3% vs. 55.5%, respectively, p=0.016), although no difference in the background variables was observed. In multivariate analysis, CD44-positivity was identified as an independent prognostic factor (hazard ratio=3.676, p=0.034). Conclusion: These data suggest that CD44-positivity might be a candidate CSC marker in IHCC and a prognostic indicator.